Jones Christy 4

What Happened Christy Jones, a director of Beta Bionics, reported two transactions dated May 21, 2026: she sold 1,998 common shares in an open-market/private sale at $9.95 per share for proceeds of $19,880, and she was granted 16,965 restricted stock units (RSUs) under the company's 2025 Equity Incentive Plan (reported with $0.00 acquisition price on the Form 4).

The sale was executed pursuant to a pre-established Rule 10b5‑1 trading plan (adopted February 19, 2026), which typically indicates a pre-arranged, routine disposition rather than an ad-hoc sale.

Key Details

• Transaction dates: May 21, 2026 (both sale and RSU grant).
• Sale: 1,998 shares @ $9.95 = $19,880 (code S). Sale made under a Rule 10b5‑1 plan (Footnote F1).
• Award: 16,965 RSUs granted (code A); reported acquisition amount $0.00 (Footnote F2: grant under 2025 Equity Incentive Plan).
• Shares owned after transaction: not specified in this filing.
• Filing date: May 26, 2026 — this is later than the usual 2-business-day Form 4 deadline (filed late).

Context

• The sale being under a 10b5‑1 plan suggests it was pre-planned and routine rather than a discretionary insider sale.
• RSU grants are awards, typically subject to vesting conditions and are not the same as an immediate cash purchase; the Form 4 lists $0.00 for the acquisition price.
• The late filing delays public disclosure of these moves; while many late filings are administrative, retail investors should note the timing when assessing insider activity.